Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
Scinai Immunotherapeutics Ltd (SCNI) - Total Liabilities
Latest total liabilities as of June 2025: $3.98 Million USD
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has total liabilities worth $3.98 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Scinai Immunotherapeutics Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Scinai Immunotherapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Scinai Immunotherapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canlan Ice Sports Corp
PINK:CNLFF
|
USA | $57.88 Million |
|
Bounty Oil & Gas NL
PINK:BYOGF
|
USA | $4.08 Million |
|
Awakn Life Sciences Corp
PINK:AWKNF
|
USA | $2.19 Million |
|
THALES - Dusseldorf Stock Exchang
DU:CSF
|
Germany | €31.82 Billion |
|
Simble Solutions Ltd
AU:SIS
|
Australia | AU$1.22 Million |
|
Sadot Group Inc.
NASDAQ:SDOT
|
USA | $49.28 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Scinai Immunotherapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scinai Immunotherapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scinai Immunotherapeutics Ltd (2000–2024)
The table below shows the annual total liabilities of Scinai Immunotherapeutics Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.47 Million | -84.25% |
| 2023-12-31 | $22.04 Million | -23.54% |
| 2022-12-31 | $28.83 Million | -7.17% |
| 2021-12-31 | $31.05 Million | +39.58% |
| 2020-12-31 | $22.25 Million | -57.51% |
| 2019-12-31 | $52.36 Million | +42.86% |
| 2018-12-31 | $36.65 Million | +401.21% |
| 2017-12-31 | $7.31 Million | +526.88% |
| 2016-12-31 | $1.17 Million | -41.45% |
| 2015-12-31 | $1.99 Million | +313.95% |
| 2014-12-31 | $481.23K | -9.16% |
| 2013-12-31 | $529.76K | +94.35% |
| 2012-12-31 | $272.58K | -39.54% |
| 2011-12-31 | $450.86K | -39.24% |
| 2010-12-31 | $742.07K | +44.75% |
| 2009-12-31 | $512.67K | +159.22% |
| 2008-12-31 | $197.78K | -94.94% |
| 2007-12-31 | $3.91 Million | +1527.92% |
| 2006-12-31 | $240.00K | -62.67% |
| 2005-12-31 | $643.00K | -38.47% |
| 2004-12-31 | $1.04 Million | -41.85% |
| 2003-12-31 | $1.80 Million | +11.48% |
| 2002-12-31 | $1.61 Million | +32140.00% |
| 2001-12-31 | $5.00K | -81.48% |
| 2000-12-31 | $27.00K | -- |